Spenser Karr
Senior Associate Corporate & Finance
-
Overview
-
Experience
-
Credentials
-
Insights and events
Spenser Karr thrives on structuring and negotiating the most complex transactions in the lifecycle of life sciences companies, working hand in hand with his clients to learn their particular needs and deliver practical, plain English advice when they need it most. Driven by a mission to accelerate the development of and expand access to life-saving therapies, Spenser is passionate about working with his clients to yield better outcomes for patients. His commitment is exemplified by his pro bono practice, where Spenser works to speed development of treatments for rare and complicated medical conditions.
Spenser's practice focuses on life sciences transactions and runs the gamut from mergers and acquisitions to collaboration and development agreements to venture capital and other investment rounds. Spenser enjoys working with companies at all stages in their life cycle, from mature public and private companies to startups, and brings a tireless work ethic to everything he does, striving to move deals forward while empowering his clients to understand the benefits and risks inherent in complicated agreements.
Representative experience
Represented PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, in its auction and subsequent $1.85 billion sale to Thermo Fisher Scientific Inc.
Represented Medical Outcomes Research Analytics in its merger with Helix Technologies, Inc., and the formation of the successor entity, Forian, Inc. (Nasdaq: FORA). *
Represented a leading global financial institution in its investment in a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines. *
Represented a leading global financial institution in its investment in a biopharmaceutical company specializing in heart disease treatment. *
Represented Tissue Analytics in its sale to Net Health, a provider of cloud-based EHR software for specialized care settings. *
Represented a pharmaceutical company developing injectable products for the treatment of allergic reactions in its acquisition by a developer of specialty pharmaceutical products. *
Represented a biomedical marketing company in its negotiations of various contracts with major pharmaceutical companies. *
Represented a clinical stage biopharmaceutical company in the negotiation of clinical trial agreements with multiple research and educational institutions. *
Represented a clinical-trial stage U.S.-based developer of medical devices in its sale to a publicly-traded, global health technology company. *
Regularly represents the national non-profit veterans organization, Folds of Honor, in its formation of local chapters. *
Represents Emily’s Entourage, a non-profit organization focused on rare mutations of cystic fibrosis, in their partnerships with clinical trial organizations.
Represented Tenable Holdings, Inc. (Nasdaq: TENB), a cybersecurity provider, in its $160 million acquisition of Accurics, Inc., a pioneer in developing cloud-native security.
*Matter handled prior to joining Hogan Lovells.
Credentials
- Juris Doctor, Temple University School of Law, summa cum laude, 2018
- MA History, Tulane University, 2012
- BA in History, Tulane University, cum laude, 2011
- Pennsylvania